However, CAR-T cell targeting of T-ALL is more complex: Analogous approaches to CD19 CAR-T cell therapy, where T cell lineage antigens, such as CD5 and CD7 (7–9), are targeted, carry risks of fratricide and T cell aplasia. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.